Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Dorzolamide Hydrochloride

FDA-approved product (solution/drops, ophthalmic), marketed as Dorzolamide Hydrochloride, Trusopt.

Registered studies
50+
Lab records
4
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Dorzolamide Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Glaucoma
  • Ocular hypertension
  • Open-angle glaucoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Carbonic anhydrase inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA44.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli39.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae27.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis86.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • M. tuberculosis: measured active in 4 of 4 lab records
Open Dorzolamide Hydrochloride in ChEMBL Registered studies below
Show the 4 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-5.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Dorzolamide Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Cosopt Versus Xalacom

    NCT00273481 · start 2005-09

    Registered record
    Registry ID
    NCT00273481
    Conditions
    Open-Angle Glaucoma; Ocular Hypertension
    Interventions
    dorzolamide 2%/timolol maleate 0.5% fixed combination; latanoprost 0.005%/timolol maleate 0.5% fixed combination; timolol maleate 0.5%; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-09
    Completion
    2007-04
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpen-Angle Glaucoma; Ocular Hypertension
    Interventiondorzolamide 2%/timolol maleate 0.5% fixed combination; latanoprost 0.005%/timolol maleate 0.5% fixed combination; timolol maleate 0.5%; placebo
    PhasePhase 4
    Registry statusCompleted

  • A 12week, Randomized, Evaluator-Masked, Parallel Group Comparing Evening Dosing Of Xalacom Vs Cosopt In Subj W/ Glaucoma

    NCT00140049 · start 2005-07

    Registered record
    Registry ID
    NCT00140049
    Conditions
    Glaucoma, Open Angle; Ocular Hypertension
    Interventions
    Xalacom; Cosopt
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-07
    Completion
    2006-07
    Enrolment
    238

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma, Open Angle; Ocular Hypertension
    InterventionXalacom; Cosopt
    PhasePhase 4
    Registry statusCompleted

  • Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension

    NCT00822055 · start 2005-05

    Registered record
    Registry ID
    NCT00822055
    Conditions
    Open-Angle Glaucoma; Ocular Hypertension
    Interventions
    brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination; dorzolamide hcl 2%/timolol maleate 0.5% fixed combination; brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy; dorzolamide hcl 2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-05
    Completion
    2006-11
    Enrolment
    140

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpen-Angle Glaucoma; Ocular Hypertension
    Interventionbrimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination; dorzolamide hcl 2%/timolol maleate 0.5% fixed combination; brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy; dorzolamide hcl 2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy
    PhasePhase 4
    Registry statusCompleted

  • Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension

    NCT00822081 · start 2005-01

    Registered record
    Registry ID
    NCT00822081
    Conditions
    Open-Angle Glaucoma; Ocular Hypertension
    Interventions
    brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination; dorzolamide hcl 2%/ timolol maleate 0.5% fixed combination; brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy.; dorzolamide hcl 2%/timolol maleate 0.5% fixed combinatin as adjunctive to current prostaglandin therapy.
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-01
    Completion
    2006-04
    Enrolment
    140

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpen-Angle Glaucoma; Ocular Hypertension
    Interventionbrimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination; dorzolamide hcl 2%/ timolol maleate 0.5% fixed combination; brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy.; dorzolamide hcl 2%/timolol maleate 0.5% fixed combinatin as adjunctive to current prostaglandin therapy.
    PhasePhase 4
    Registry statusCompleted

  • A Comparison of the Effect of Dorzolamide and Timolol on Optic Disk Blood Flow in Patients With Open Angle Glaucoma

    NCT00991822 · start 1999-05

    Registered record
    Registry ID
    NCT00991822
    Conditions
    Glaucoma, Open-Angle
    Interventions
    Dorzolamide 2%; Timolol 0.5%
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    1999-05
    Completion
    2003-12
    Enrolment
    160

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma, Open-Angle
    InterventionDorzolamide 2%; Timolol 0.5%
    PhasePhase 2 / Phase 3
    Registry statusCompleted